Navigation Links
2-step ovarian cancer immunotherapy made from patients' own tumor shows promise
Date:4/6/2013

WASHINGTON, D.C. As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

The immunotherapy has two steps a personalized dendritic cell vaccination and adoptive T-cell therapy. The team reports that in the study of 31 patients, vaccination therapy alone showed about a 61 percent clinical benefit, and the combination of both therapies showed about a 75 percent benefit.

The findings offer new hope for the large number of ovarian cancer patients who relapse following treatment. The first step of the immunotherapy approach is to preserve the patient's tumor cells alive, using sterile techniques at the time of surgery so they can be used to manufacture a personalized vaccine that teaches the patient's own immune system to attack the tumor. Then, the Penn Medicine team isolates immune cells called dendritic cells from patients' blood through a process called apheresis, which is similar to the process used for blood donation. Researchers then prepare each patient's personalized vaccine by exposing her dendritic cells to the tumor tissue that was collected during surgery.

Because ovarian cancer symptoms can be stealth and easily mistaken for other issues constipation, weight gain, bloating, or more frequent urination more than 60 percent of patients are diagnosed only after the disease has spread to their lymph nodes or other distant sites in the body, when treatment is much less likely to produce a cure compared to when the disease is detected early. As the fifth leading cause of cancer-related deaths among women in the United States, it takes the lives of more than 14,000 women each year.

"Given these grim outcomes, there is definitely a vast unmet need for the development of novel, alternate therapies," said lead author Lana Kandalaft, PharmD, PhD, MTR, a research assistant professor of Obstetrics and Gynecology and director of clinical development and operations in Penn Medicine's Ovarian Cancer Research Center. "This is the first time such a combination immunotherapy approach has been used for patients with ovarian cancer, and we believe the results are leading us toward a completely new way to treat this disease."

Both treatments are given in conjunction with bevacizumab, a drug that controls the blood vessel growth that feeds tumors. Combining bevacizumab with immunotherapy makes a powerful duo, Kandalaft says. The vaccine trial is still open to accrual to test new combinatorial strategies.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. 12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse
2. 2-step immunotherapy attacks advanced ovarian cancer
3. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
4. U.S. Panel Rejects Ovarian Cancer Screening
5. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
6. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
7. The prevention of hereditary breast and ovarian cancer by PGD is feasible
8. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
9. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
10. Benefit of PET and PET/CT in ovarian cancer is not proven
11. Mechanisms of acquired chemoresistance in ovarian cancer identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... There was a time when tampons and ... going with the flow and turning to menstrual cups, like Lunette . To make ... is introducing their new anthem in this catchy video ! , It’s easy ...
(Date:5/25/2016)... ... 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist who leads ... MO 63366. He serves patients of all ages with a full menu of dental ... is reflected in the superior patient reviews that he has consistently earned during his ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... services and products in the developing world, is pleased to release their 2015 ... over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... its annual Medical and Prescription Drug survey , an employee benefits ... survey, which was conducted in December 2015, indicates that employers are turning to ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
(Date:5/25/2016)... , May 25, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Insulin Pump and Others)" published by P&S Market Research, ... $9,998.3 million in 2015, and it is expected to ... on type, the insulin pump segment is expected to ...
Breaking Medicine Technology: